APT vs LAKE vs CTAS vs MSA vs SRPT

For growth investors, Lakeland Industries, Inc.

(LAKE) is the stronger pick with 34. 1% revenue growth year-over-year, versus 2. 3% for Alpha Pro Tech, Ltd. (APT). Alpha Pro Tech, Ltd. (APT) offers the better valuation at 19. 6x trailing P/E, making it the more compelling value choice. Analysts rate Lakeland Industries, Inc. (LAKE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alpha Pro Tech, Ltd.

(APT) is the cheapest at 19. 6x versus Cintas Corporation at 38. 6x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 6. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: MSA Safety Incorporated wins at 1. 13x versus Cintas Corporation's 2. 08x — a reasonable growth-adjusted valuation.

Over the past 5 years, Cintas Corporation (CTAS) delivered a total return of +95.

8%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: CTAS returned +685. 0% versus SRPT's +18. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alpha Pro Tech, Ltd.

(APT) is the lower-risk stock at 0. 48β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 319% more volatile than APT relative to the S&P 500. On balance sheet safety, Alpha Pro Tech, Ltd. (APT) carries a lower debt/equity ratio of 13% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lakeland Industries, Inc.

(LAKE) is pulling ahead at 34. 1% versus 2. 3% for Alpha Pro Tech, Ltd. (APT). On earnings-per-share growth, the picture is similar: Cintas Corporation grew EPS 16. 1% year-over-year, compared to -437. 5% for Lakeland Industries, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cintas Corporation (CTAS) is the more profitable company, earning 17.

5% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTAS leads at 22. 8% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, MSA Safety Incorporated (MSA) is the more undervalued stock at a PEG of 1. 13x versus Cintas Corporation's 2. 08x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Sarepta Therapeutics, Inc. (SRPT) trades at 6. 9x forward P/E versus 34. 8x for Cintas Corporation — 27. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MSA: 36. 7% to $235. 00.

In this comparison, MSA (1.

2% yield), LAKE (1. 1% yield), CTAS (0. 9% yield) pay a dividend. APT, SRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cintas Corporation (CTAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51), 0. 9% yield, +685. 0% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTAS: +685. 0%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (APT (Industrials) and LAKE (Consumer Cyclical) and CTAS (Industrials) and MSA (Industrials) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: APT is a small-cap quality compounder stock; LAKE is a small-cap high-growth stock; CTAS is a mid-cap quality compounder stock; MSA is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock. LAKE, CTAS, MSA pay a dividend while APT, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.